Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis
Bryan C. Tan, Xin‐Hui Pan, Han Shi Jocelyn Chew, et al.
International Journal of Obesity (2023) Vol. 47, Iss. 8, pp. 677-685
Closed Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database
Jianxing Zhou, You Zheng, Baohua Xu, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 34
Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis
Xin‐Hui Pan, B.C. Tan, Yip Han Chin, et al.
Obesity (2024) Vol. 32, Iss. 5, pp. 840-856
Closed Access | Times Cited: 20
Semaglutide (Ozempic®) Use in Denmark 2018 Through 2023 ‒ User Trends and off-Label Prescribing for Weight Loss
Aurélie Mailhac, Lars C. Pedersen, Anton Pottegård, et al.
Clinical Epidemiology (2024) Vol. Volume 16, pp. 307-318
Open Access | Times Cited: 17
Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age
Giuseppe Lisco, Olga Disoteo, Anna De Tullio, et al.
Nutrients (2023) Vol. 16, Iss. 1, pp. 63-63
Open Access | Times Cited: 31
Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials
Wenting Cai, Ruobin Zhang, Yao Yao, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access | Times Cited: 16
Potent incretin‐based therapy for obesity: A systematic review and meta‐analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety
Alberte Laura Oest Müllertz, Rasmus Michael Sandsdal, Simon Birk Kjær Jensen, et al.
Obesity Reviews (2024) Vol. 25, Iss. 5
Open Access | Times Cited: 15
Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population
Nicholas Chew, Xin Pan, Bryan Chong, et al.
Diabetes Research and Clinical Practice (2024) Vol. 211, pp. 111652-111652
Closed Access | Times Cited: 11
Associations of metabolic disorders with hypertension and cardiovascular disease: recent findings and therapeutic perspectives
Atsushi Tanaka, Koichi Node
Hypertension Research (2024) Vol. 47, Iss. 12, pp. 3338-3344
Closed Access | Times Cited: 9
Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials
Ligang Liu, Hekai Shi, Merilyn Xie, et al.
International Journal of Clinical Pharmacy (2024) Vol. 46, Iss. 6, pp. 1268-1280
Open Access | Times Cited: 9
Non-canonical G protein signaling
Bernd Nürnberg, Sandra Beer‐Hammer, Ellen Reisinger, et al.
Pharmacology & Therapeutics (2024) Vol. 255, pp. 108589-108589
Open Access | Times Cited: 7
Efficacy and Safety of Novel Twincretin Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, as an Anti-obesity Medicine in Individuals Without Diabetes: A Systematic Review and Meta-analysis
Deep Dutta, A B Kamrul-Hasan, Lakshmi Nagendra, et al.
touchREVIEWS in Endocrinology (2024) Vol. 20, Iss. 2
Open Access | Times Cited: 7
Newer pharmacological interventions directed at gut hormones for obesity
Michael Camilleri, Andrés Acosta
British Journal of Pharmacology (2023) Vol. 181, Iss. 8, pp. 1153-1164
Closed Access | Times Cited: 14
The prognostic value of metabolic dysfunction‐associated steatotic liver disease in acute myocardial infarction: A propensity score‐matched analysis
Gwyneth Kong, Grace Cao, Jaycie Koh, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 8, pp. 3328-3338
Closed Access | Times Cited: 5
Can tirzepatide untie the Gordian knot of eating disorders among individuals with type 2 diabetes and obesity?
Dimitrios Patoulias, Paschalis Karakasis, Mohamed El‐Tanani, et al.
Journal of Diabetes and its Complications (2024) Vol. 38, Iss. 8, pp. 108812-108812
Closed Access | Times Cited: 5
The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: a narrative review focusing on principal risk modifiers
Amedeo Lonardo
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 10, pp. 891-911
Closed Access | Times Cited: 12
Role of Incretin Mimetics in the Management of Obesity
Shilpa Chugh Garcha, Sanjay Kalra
(2025), pp. 77-100
Closed Access
Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review
Abdullah Al Lawati, Ayman Alhabsi, R. Rahul, et al.
Diseases (2025) Vol. 13, Iss. 5, pp. 129-129
Open Access
The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials
Ligang Liu, Hekai Shi, Merilyn Xie, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 5, pp. 668-668
Open Access
The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjects
Yue Liu, Wei Chen, Xuemei He, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Discontinuing glucagon‐like peptide‐1 receptor agonists and body habitus: A systematic review and meta‐analysis
Sara Berg, Hannah Stickle, Suzanne J. Rose, et al.
Obesity Reviews (2025)
Closed Access
The Use of an Artificial Intelligence Platform OpenEvidence to Augment Clinical Decision-Making for Primary Care Physicians
Ryan T. Hurt, Christopher R. Stephenson, Elizabeth A. Gilman, et al.
Journal of Primary Care & Community Health (2025) Vol. 16
Open Access
Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese Individuals: A Narrative Review
Mohammed Sallam, Johan Snygg, Sara El Ghandour, et al.
Obesities (2025) Vol. 5, Iss. 2, pp. 26-26
Open Access
Is Tirzepatide the New Game Changer in Type 2 Diabetes?
Giuseppe Lisco, Olga Disoteo, Vincenzo De Geronimo, et al.
Endocrines (2024) Vol. 5, Iss. 1, pp. 72-86
Open Access | Times Cited: 3
Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database
Jianxing Zhou, Wei Huang, Y. Xie, et al.
Endocrine (2024)
Closed Access | Times Cited: 3
Efficacy and safety of tirzepatide in overweight or obese adults without diabetes: systematic review and meta-analysis of randomized controlled trials
Ligang Liu, Milap C. Nahata, Hekai Shi, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top